How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.
about
Deep molecular responses for treatment-free remission in chronic myeloid leukemiaCurrent developments in molecular monitoring in chronic myeloid leukemiaLow body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia.Is a cure for CML without allogeneic stem cell transplantation around the corner?Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentImatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.CML as Part of Dual Malignancies-A Retrospective Analysis: Possible Mechanisms and Review of Literature.Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.'Real-life' study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis.Need to minimize bias when surveying patient attitudes to stopping cml treatment.gDNA Q-PCR for clinical monitoring of CML.Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia.Dasatinib dose management for the treatment of chronic myeloid leukemia.How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.Deep molecular response in chronic myelogenous leukemia: ensuring accuracy and consistency.
P2860
Q26745594-0FB408BD-018E-4EE2-831A-1736F56042F8Q28066148-1187AE94-9CA8-435E-A126-BEBC1FE43E62Q33595519-A8793D0D-8FD9-4D23-8F54-057779C4039AQ34302448-71744679-2B85-4DF6-B71A-226E35A54852Q36288815-42A98DE1-C65F-4186-9A1A-256EBD018FC8Q37237918-B8D599F5-BD1B-4D88-92CE-EED91971B3ADQ38585916-1F3E278E-7735-4904-A923-C4F2AE302B4AQ38866390-E4A66183-6A54-497F-8635-834891C834FDQ38937497-B0220C5A-EC6B-460A-B7E1-836D1566AEC9Q38998221-6C4C224F-9836-44A2-8616-46792D089E0AQ39028177-919534D2-3D55-4B67-AF02-38E9FFE0A17BQ39672189-03C50D2C-3A2B-484F-A1F6-11542ADE909CQ42178146-AFA9C323-B50A-4361-839A-6DCE300CAAA2Q42910340-C21E92C0-F1FC-42F6-86E4-3688500D008CQ43068057-C49B4A50-91FD-403D-A7B6-ABC74E7F414EQ48165102-1B49B113-6A0C-405C-B940-CD0E87903F5BQ54212463-931B6D30-E94A-44B3-B98A-26BA3DDC32F9Q55025022-4730F36E-8492-40DC-9941-2B5BB2844591Q55060580-1EF627AE-3261-4035-BBEE-D742758DEE65
P2860
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
How I determine if and when to ...... for chronic myeloid leukaemia.
@en
type
label
How I determine if and when to ...... for chronic myeloid leukaemia.
@en
prefLabel
How I determine if and when to ...... for chronic myeloid leukaemia.
@en
P2860
P356
P1476
How I determine if and when to ...... for chronic myeloid leukaemia
@en
P2093
Timothy P Hughes
P2860
P356
10.1111/BJH.12892
P407
P50
P577
2014-04-23T00:00:00Z